Abdallah Hossam M, El-Halawany Ali M, Darwish Khaled M, Algandaby Mardi M, Mohamed Gamal A, Ibrahim Sabrin R M, Koshak Abdulrahman E, Elhady Sameh S, Fadil Sana A, Alqarni Ali A, Abdel-Naim Ashraf B, Elfaky Mahmoud A
Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
Plants (Basel). 2022 Jul 24;11(15):1914. doi: 10.3390/plants11151914.
Since the emergence of the pandemic of the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the discovery of antiviral phytoconstituents from medicinal plants against SARS-CoV-2 has been comprehensively researched. In this study, thirty-three plants belonging to seventeen different families used traditionally in Saudi Arabia were tested in vitro for their ability to inhibit the SARS-CoV-2 main protease (M). Major constituents of the bio-active extracts were isolated and tested for their inhibition potential against this enzyme; in addition, their antiviral activity against the SARS-CoV-2 Egyptian strain was assessed. Further, the thermodynamic stability of the best active compounds was studied through focused comparative insights for the active metabolites regarding ligand-target binding characteristics at the molecular level. Additionally, the obtained computational findings provided useful directions for future drug optimization and development. The results revealed that , , and extracts showed a high percentage of inhibition of 66.4, 58.7, and 31.5%, against SARS-CoV-2 M, respectively. The major isolated constituents of these plants were identified as gardenins A and B (from ), 6-gingerol and 6-paradol (from ), and thymoquinone (from ). These compounds are the first to be tested invitro against SARS-CoV-2 M. Among the isolated compounds, only thymoquinone (THY), gardenin A (GDA), 6-gingerol (GNG), and 6-paradol (PAD) inhibited the SARS-CoV-2 M enzyme with inhibition percentages of 63.21, 73.80, 65.2, and 71.8%, respectively. In vitro assessment of SARS-CoV-2 (hCoV-19/Egypt/NRC-03/2020 (accession number on GSAID: EPI_ISL_430820) revealed a strong-to-low antiviral activity of the isolated compounds. THY showed relatively high cytotoxicity and was anti-SARS-CoV-2, while PAD demonstrated a cytotoxic effect on the tested VERO cells with a selectivity index of CC/IC = 1.33 and CC/IC = 0.6, respectively. Moreover, GNG had moderate activity at non-cytotoxic concentrations in vitro with a selectivity index of CC/IC = 101.3/43.45 = 2.3. Meanwhile, GDA showed weak activity with a selectivity index of CC/IC = 246.5/83.77 = 2.9. The thermodynamic stability of top-active compounds revealed preferential stability and SARS-CoV-2 M binding affinity for PAD through molecular-docking-coupled molecular dynamics simulation. The obtained results suggest the treating potential of these plants and/or their active metabolites for COVID-19. However, further in-vivo and clinical investigations are required to establish the potential preventive and treatment effectiveness of these plants and/or their bio-active compounds in COVID-19.
自严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发冠状病毒病(COVID-19)大流行以来,针对药用植物中抗SARS-CoV-2的抗病毒植物成分的发现进行了全面研究。在本研究中,对沙特阿拉伯传统使用的属于17个不同科的33种植物进行了体外测试,以检测它们抑制SARS-CoV-2主要蛋白酶(M)的能力。分离出生物活性提取物的主要成分,并测试它们对该酶的抑制潜力;此外,评估了它们对SARS-CoV-2埃及毒株的抗病毒活性。此外,通过对活性代谢物在分子水平上的配体-靶点结合特征进行重点比较分析,研究了最佳活性化合物的热力学稳定性。此外,获得的计算结果为未来药物优化和开发提供了有用的方向。结果显示,[植物名称1]、[植物名称2]和[植物名称3]提取物对SARS-CoV-2 M的抑制率分别高达66.4%、58.7%和31.5%。这些植物中分离出的主要成分被鉴定为栀子苷A和B(来自[植物名称1])、6-姜酚和6-对甲酚(来自[植物名称2])以及百里醌(来自[植物名称3])。这些化合物是首次在体外针对SARS-CoV-2 M进行测试。在分离出的化合物中,只有百里醌(THY)、栀子苷A(GDA)、6-姜酚(GNG)和6-对甲酚(PAD)对SARS-CoV-2 M酶有抑制作用,抑制率分别为63.21%、73.80%、65.2%和71.8%。对SARS-CoV-2(hCoV-19/埃及/NRC-03/2020(GSAID上的登录号:EPI_ISL_430820)的体外评估显示,分离出的化合物具有从强到弱的抗病毒活性。THY显示出相对较高的细胞毒性且具有抗SARS-CoV-2作用,而PAD对测试的VERO细胞表现出细胞毒性作用,选择性指数CC/IC分别为1.33和0.6。此外,GNG在体外非细胞毒性浓度下具有中等活性,选择性指数CC/IC = 101.3/43.45 = 2.3。同时,GDA表现出较弱的活性,选择性指数CC/IC = 246.5/83.77 = 2.9。通过分子对接耦合分子动力学模拟,顶级活性化合物的热力学稳定性显示出PAD具有优先稳定性和对SARS-CoV-2 M的结合亲和力。获得的结果表明这些植物和/或其活性代谢物对COVID-19具有治疗潜力。然而,需要进一步的体内和临床研究来确定这些植物和/或其生物活性化合物在COVID-19中的潜在预防和治疗效果。